Record breaking revenue of HK$586.2M and EPS increased to HK$1.56 cents
Dividend distributed for two consecutive years
Launching innovation-driven transformation to become a global leader in regenerative medicine
Hong Kong SAR – EQS Newswire – 27 March 2026 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, Stock Code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).
Major achievements in 2025
During the year, the Group achieved several achievements for both its marketed products and innovative biologics. Main attractions include:
- During the year, the Group delivered record-breaking financial results, with revenues increasing by 6.0% year-on-year (“YoY”), reaching approximately HK$586.2 million. Profit for the year increased 12.7% year-on-year to approximately HK$93.3 million, and net profit margin increased 1.0 percentage points year-on-year to 15.9%, a historic high. Earnings per share reached approximately HK$1.56 cents, representing growth of 15.5% YoY or a CAGR of 18.55% from 2023 to 2025.
- The group generated solid cash from operations in the year, with operating cash flow and free cash flow growing by 32.7% and 27.3% respectively. Cash ratio to increase from 0.53x at end-2024 to 1.63x at end-2025. Cash conversion cycle increased from 124 days to 107 days, highlighting greater operational efficiency. Supported by sustainable earnings and healthy cash flow, the Board of Directors (the “Board”) has declared a dividend payment of HK$0.313 cents per share for 2025.
- Since its official launch in March 2024, Bogutai® Strong growth momentum has been maintained, driven by a solid commercialization strategy and successful academic engagement. In 2025, Bogutai® Demonstrated rapid market adoption in China, achieving significant revenue growth of 111.0% year-on-year.
- In May 2025, the group’s second ophthalmology product, 金因康® (Diquafosol Sodium Eye Drops) received marketing approval from the National Medical Products Administration of China (“NMPA”), an important milestone in the expansion of the Group’s ophthalmic portfolio after Genesoft.®. The group is actively preparing its launch and marketing strategy. In addition to leveraging the synergy with GeneSoft® And its established online and offline distribution network for rapid market entry, 金因康® Will specifically target the mid to high-end segment of dry eye patients outside the hospital setting, who prioritize long-term efficacy and premium product quality.
- In June 2025, the group officially launched the high-end series GeneQueens® of flesh® and medical equipment brand 金因敷®Marking two major milestones in its strategic expansion into the integrated “Drug, Medical Device and Aesthetics” sector. These product launches reflect the Group’s commitment to enhancing its skin health product matrix and addressing growing consumer needs for efficacy-driven, medical-grade skin care in both functional skin care and post-aesthetic recovery.
- In July 2025, the marketing application for isavuconazonium sulphate capsules was officially accepted by the NMPA. Isavuconazonium sulphate capsules are expected to be approved for launch in the fourth quarter of 2026, providing a safer, more effective and higher quality treatment option for patients suffering from invasive fungal infections.
- In 2025, the Group established a strategic partnership with Wenzhou Medical University to explore thermosensitive gel formulations combining EGF and bFGF, taking advantage of the university’s proven expertise in bFGF production. As a key growth factor in regenerative medicine, bFGF is highly effective in promoting granulation and angiogenesis.
- At the end of 2025, the Group changed its long-term strategy from “sustainable growth” to “innovation-driven”, marking a bold transformation from an integrated pharmaceutical company to a global leader in regenerative medicine. The Group is pursuing a transformative R&D strategy spanning four key areas: muscle-skeletal regeneration, skin regeneration, ophthalmic regeneration, and ENT regeneration.
annual Result
For 2025, the group reported revenues of approximately HK$586.2 million, representing an increase of 6.0% year-on-year. revenue from bogutai® increased from approximately HK$63.5 million to approximately HK$134.0 million, representing a significant increase of 111.0%. Revenue generated from Genetime® was approximately HK$220.4 million, representing an increase of 10.9% year-on-year. genesoft® Revenue declined 7.9% year-on-year, from approximately HK$41.9 million to approximately HK$38.6 million, due to intense market competition. pin up® Revenue for the year decreased by 29.4% from approximately HK$244.2 million to approximately HK$172.5 million. In 2025, the group adopted a more disciplined and selective hospital-supply strategy under volume-based purchasing (VBP) to protect margins, especially in areas where policy adjustments intensified price competition. Additionally, the Group accelerated diversification into pharmacy networks beyond traditional hospital channels and optimized its supply chain to improve costs and profitability. In 2024, Boshutai® Henan was successfully incorporated into the VBP by the Seventeen Provinces Alliance and the procurement validity period is set for two years. Hospitals in many provinces started purchasing Boshutai® In 2025. Revenue from Boshutai, after destocking and low base, in 2024® increased from approximately HK$10.2 million to approximately HK$15.5 million, representing a significant increase of 51.9%. physique® Generated revenues of approximately HK$2.8 million in its initial phase. The limited revenue scale reflected several factors, including the relatively small number of products approved and launched during the year, and the fact that specialized marketing and distribution teams were still being built and optimized.
Gross profit was approximately HK$487.6 million, representing an increase of 5.7% compared to approximately HK$461.1 million in 2024, and gross profit margin increased 0.2 percentage points year-on-year to 83.2%. The group achieved another year of record-breaking profits, achieving approximately HK$93.3 million this year, representing an increase of 12.7% year-on-year. Net profit margin increased 1.0 percentage points year-on-year to 15.9%. These results demonstrate the Group’s success in converting product innovation into market value through strong commercialization execution and financial discipline. Earnings per share reached approximately HK$1.56 cents, representing an increase of 15.5% year-on-year.
possibilities
Regenerative medicine has emerged as a rapidly growing field that focuses on repairing, replacing or regenerating damaged tissues or organs using cells, tissues or genetic material. This field has the potential to treat and resolve the underlying causes of chronic and advanced diseases. The global regenerative medicine market is estimated to be worth approximately USD51.7 billion in 2025. It is projected to grow from USD63.0 billion in 2026 to USD555.6 billion by 2034, representing a compound annual growth rate (CAGR) of 31.3%. The increasing prevalence of chronic and hereditary diseases along with rising healthcare expenditure in both developed and emerging markets is expected to support continued growth in the regenerative medicine industry.
Mr. Kingsley Leung, President of Uni-Bio Sciencecommented, “In 2025, we are proud to deliver another year of record profitability, an important milestone in our growth journey. During the year, we entered a new phase of strategic growth. In anticipation of an increasingly favorable market environment, we advanced our strategic transition from ‘steady growth’ to ‘innovation-driven’ growth with a clear focus on four diverse therapeutic areas: Musculoskeletal Regeneration, Skin Regeneration, Ophthalmic Regeneration, and ENT Regeneration.
With multiple products moving through our pipeline and rapidly moving towards commercialization, the Group continues to expand its marketing channels. In addition to strengthening our established offline hospital network, deepening partnerships with local distributors and hosting academic conferences, we have actively expanded into online e-commerce platforms to enhance product penetration and expand our market reach. Our ambitions extend far beyond China. During the year, we formed a strategic partnership with Kexing Biopharm to accelerate Bogutai’s global expansion®. Through this collaboration, we have granted exclusive commercialization rights for Bogutai to Kexing Biopharma® in six international markets—Saudi Arabia, Egypt, Morocco, Colombia, Argentina and Mexico—creating a solid foundation for global growth. We expect these markets to start contributing to revenues by the end of 2026. Additionally, we are advancing the FDA approval process for Bogutai.® In the United States, approval is targeted for 2027.
In December, we entered into a strategic cooperation with Wenzhou Medical University and the People’s Government of Ouhai District, Wenzhou, to promote a synergistic ‘government-university-enterprise’ model, to further strengthen our capabilities in regenerative medicine. Supported by strong partnerships with local governments and leading academic institutions, we are well-positioned to build a world-class biomedical ecosystem and enhance our end-to-end innovation capabilities.
Hashtag: #Uni-Bioscience
The issuer is solely responsible for the content of this announcement.
